Radiation Dermatitis Clinical Trial
Official title:
Using Autologous Epidermal Skin Micrografts to Improve Healing In Radiation Wounds: A Pilot Study
Patients undergoing radiation for the treatment of malignancies may suffer from side effects to the skin in the form of radiation dermatitis. This can lead to local wound formation with poor healing. Treatment options for the resulting wound can range from watchful waiting to more aggressive debridement and secondary grafting. Epidermal grafting is a technique in which autologous epidermis is used to cover wounds that are larger than the donor site. Previous studies have demonstrated that this is an effective treatment for different wounds and ulcers but its utility has not yet been evaluated for the treatment of radiation induced injuries. The CelluTome Epidermal Grafting System is a semi automated device that allows easy formation of epidermal Blister. Our study will evaluate the efficacy of epidermal grafts collected using the CelluTome device in the treatment of radiation dermatitis.
Status | Recruiting |
Enrollment | 34 |
Est. completion date | December 2028 |
Est. primary completion date | March 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Status post radiation treatment, with radiation-induced wound. This includes patient with moist desquamation as well as full epidermal necrosis and superficial dermal ulcerations, this wound would otherwise be allowed to heal by secondary intention; - Having suitable areas of treatment: All wounds in the area of interest must be at least 20 cm2 (~10 cm2 per treatment/control area); - The radiation injury must have a suitable adjacent irradiated control site before initiation of treatment. This will be determined by objective measurements of % wound epithelization, wound erythema, pliability, induration and thickness at enrollment; - Able and willing to comply with all visit, treatment and evaluation schedules and requirements; - Wound considered appropriate by physician to receive epidermal grafting; - Able to understand and provide written informed consent; Exclusion Criteria: - Active tanning, including the use of tanning booths, during the course of the study; - Study wound exhibits clinical signs and symptoms of infection at the screening/enrollment visit; - Patient unable to provide donor site for epidermal harvesting; - Wound sites located on the face, hands or feet - Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists; - History of collagen vascular disease; - Active Herpes Simplex or Zoster at the time of treatment or having experienced more than three episodes of Herpes Simplex / Zoster eruption within a year of study enrollment; - History of immunosuppression/immune deficiency disorders (including human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) or use of immunosuppressive medications; - Significant concurrent illness, such as uncontrolled diabetes (with a hemoglobin A1C of more than 8) (i.e., any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process); - Mentally incompetent, prisoner or evidence of active substance or alcohol abuse; - Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or study personnel) to treat the subject as part of this research study; - Participation in another interventional study with potential exposure to an investigational drug within past 30 days; - Pregnant females, due to possible discomfort with the procedure even though the procedure is localized and there is no new drug. |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital, Wellman Center for Photomedicine | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | 3M |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events v5) grading | Patients will receive a grading for their treated radiation wound based on the CTCAE. Changes in the grading over time will be used to assess improvement of the wound | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06040983 -
Clinical Investigation on the Treatment of Radiation Induced Dermatitis With FR-101 Chest Dressing
|
N/A | |
Withdrawn |
NCT05505214 -
Topical Steroids & Bacterial Decolonization for Radiation Dermatitis
|
Phase 2 | |
Withdrawn |
NCT04593914 -
A Novel Skin Barrier Protectant for Acute Radiodermatitis
|
N/A | |
Completed |
NCT05450848 -
StrataXRT vs. Standard Clinical Practice in the Prevention and Treatment of Radiation Dermatitis
|
N/A | |
Active, not recruiting |
NCT05594498 -
A Study of StrataXRT in the Prevention of Radiation Dermatitis in Breast Cancer Patients
|
N/A | |
Recruiting |
NCT04110977 -
A Reminder App to Reduce Radiation Dermatitis Rates in Patients With Head-and-Neck Cancer
|
N/A | |
Recruiting |
NCT06158347 -
Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients With Localized Breast Cancer
|
N/A | |
Recruiting |
NCT05553392 -
StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis
|
N/A | |
Active, not recruiting |
NCT04268056 -
Characterization of Skin Microbiome Profile and it's Correlation to Radiation Dermatitis
|
||
Not yet recruiting |
NCT04888234 -
Evaluation the Effectiveness of Ru-Yi-Jin-Huang Powder for the Radiation-induced Dermatitis.
|
Phase 2 | |
Terminated |
NCT01597921 -
A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer
|
N/A | |
Completed |
NCT00481884 -
Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients
|
Phase 3 | |
Completed |
NCT03494205 -
Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis
|
Phase 2 | |
Completed |
NCT05810194 -
Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis
|
||
Completed |
NCT03941665 -
Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients
|
N/A | |
Not yet recruiting |
NCT02051907 -
Clinical Study to Evaluate Safety and Efficacy of KAM1403 Gel to Treat Radiation Dermatitis
|
Phase 2 | |
Completed |
NCT02839473 -
Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial
|
Phase 3 | |
Completed |
NCT00573365 -
LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis
|
N/A | |
Completed |
NCT00876642 -
Trial Comparing Best Supportive Care to Aloe Vera Gel
|
Phase 3 |